BioSpace News Archive

FDA

6 FDA Decisions To Watch in Q1 2026

After greenlighting 56 novel therapeutics in 2025, four notable applications continue to await the agency’s action after being delayed from the fourth quarter last year.

January 12, 2026
·
8 min read
·
Tristan Manalac
Drug Development

Biopharma Momentum To Propel Rare Disease, Cancer, Neuro Forward in 2026

After years stuck in the “doldrums,” the biopharma sector is in a “very good place” heading into the new year, analysts told BioSpace, with both rare and chronic diseases headlining investor and R&D interest as JPM26 kicks off.

January 12, 2026
·
6 min read
·
Heather McKenzie
Opinion

To Broaden Access to CAR Ts, Mitigate Their Side Effects

The prevalence of serious inflammatory safety issues such as cytokine release syndrome and immune effector cell–associated neurotoxicity syndrome limits the reach of these transformative cancer therapies.

January 12, 2026
·
4 min read
·
Teresa Whalen
Venture capital

Early-Stage Biotechs Feel the Squeeze as Funding Favors Derisked Assets: JPM

Heightened diligence standards and longer decision timelines for early-stage startups slowed venture activity last year, J.P. Morgan found in a report published ahead of the bank’s annual healthcare conference in San Francisco.

January 12, 2026
·
2 min read
·
Nick Paul Taylor